These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 8873503)

  • 21. Two cases of monostotic Paget's disease: effects of bisphosphonate.
    Hoshiro M; Harada T; Iwai H; Miyatake T; Nishimura A; Ohno Y; Aoki N
    Endocr J; 2003 Aug; 50(4):385-92. PubMed ID: 14599111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term intravenous therapy with Neridronate in Paget's disease.
    Adami S; Bevilacqua M; Broggini M; Filipponi P; Ortolani S; Palummeri E; Ulivieri F; Nannipieri F; Braga V
    Clin Exp Rheumatol; 2002; 20(1):55-8. PubMed ID: 11892710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.
    Miller PD; Brown JP; Siris ES; Hoseyni MS; Axelrod DW; Bekker PJ
    Am J Med; 1999 May; 106(5):513-20. PubMed ID: 10335722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE; Barrett-Connor EL; Schwartz A; Santora AC; Bauer DC; Suryawanshi S; Feldstein A; Haskell WL; Hochberg MC; Torner JC; Lombardi A; Black DM;
    J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of two different bisphosphonates on Paget's disease of bone: ICTP assessed.
    Filipponi P; Pedetti M; Beghe F; Giovagnini B; Miam M; Cristallini S
    Bone; 1994; 15(3):261-7. PubMed ID: 8068446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
    Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group.
    Bone HG; Greenspan SL; McKeever C; Bell N; Davidson M; Downs RW; Emkey R; Meunier PJ; Miller SS; Mulloy AL; Recker RR; Weiss SR; Heyden N; Musliner T; Suryawanshi S; Yates AJ; Lombardi A
    J Clin Endocrinol Metab; 2000 Feb; 85(2):720-6. PubMed ID: 10690882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of intravenous alendronate in Paget's disease of bone.
    O'Doherty DP; McCloskey EV; Vasikaran S; Khan S; Kanis JA
    J Bone Miner Res; 1995 Jul; 10(7):1094-100. PubMed ID: 7484285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
    Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
    Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of two oral doses of alendronate in the treatment of Paget's disease of bone.
    Adami S; Mian M; Gatti P; Rossini M; Zamberlan N; Bertoldo F; Lo Cascio V
    Bone; 1994; 15(4):415-7. PubMed ID: 7917580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
    Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
    J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
    Stuckey BG; Lim EM; Kent GN; Ward LC; Gutteridge DH
    J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis.
    Cryer B; Binkley N; Simonelli C; Lewiecki EM; Lanza F; Chen E; Petruschke RA; Mullen C; de Papp AE
    Am J Geriatr Pharmacother; 2005 Sep; 3(3):127-36. PubMed ID: 16257815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of drugs for Paget's disease of bone.
    Reginster JY; Lecart MP
    Bone; 1995 Nov; 17(5 Suppl):485S-488S. PubMed ID: 8573423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy.
    Cundy T; Wheadon L; King A
    J Bone Miner Res; 2004 May; 19(5):703-11. PubMed ID: 15068492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
    Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The methodology of clinical trials of oral tiludronate in Paget's disease of bone.
    Roux C
    Bone; 1995 Nov; 17(5 Suppl):497S-499S. PubMed ID: 8573426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.